Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CR20BA5-2
- Development stage
- Preclinical
- Lead developer
- China Resources Pharmaceutical Holdings
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
CR20BA5-2 is a novel tetravalent bispecific antibody (bsAb) designed to simultaneously target and neutralize interleukin-23 (IL-23) and tumor necrosis factor-like ligand 1A (TL1A). Developed by China Resources Biopharmaceutical, the therapeutic candidate is being investigated for the treatment of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. By co-targeting IL-23 (specifically binding to its p19 subunit) and TL1A, CR20BA5-2 aims to achieve synergistic anti-inflammatory efficacy and provide a therapeutic option for patients with refractory or treatment-resistant IBD.
02
Targets
IL23A (Interleukin-23 p19 Subunit)IL23R (Interleukin-23 Receptor)DR3 (Tumor necrosis factor receptor superfamily member 25)TL1A (TNF-like cytokine 1A)
Beyond the preview
Go deeper on CR20BA5-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CR20BA5-2.